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Introduction
Methamphetamine is a widely abused illicit drug with approximately 1.2 million reported users in the United States (Volkow, 2013) . Also known as "meth", "crystal", "speed" or "ice", methamphetamine is a potent and highly addictive central nervous stimulant that acts by inhibition and reversal of neurotransmitter transporters of dopamine, norepinephrine, and serotonin (Carvalho et al., 2012; Panenka et al., 2013) . Illicit methamphetamine is sold as either a racemic mixture or the d-methamphetamine isomer since the dextro isomer is much more psychoactive (de la Torre et al., 2004) . High or repeated doses of methamphetamine can affect multiple organ systems, leading to profound neurotoxicity, cardiotoxicity, acute renal failure, and pulmonary toxicity (Volkow et al., 2010; Carvalho et al., 2012) .
Following oral, inhalation, or intranasal administration, methamphetamine is wellabsorbed into the bloodstream (Harris et al., 2003; Schep et al., 2010) and is distributed into many organs with the highest uptake occurring in lungs, liver, brain, and kidneys (Volkow et al., 2010) . Methamphetamine is eliminated by both hepatic metabolism and renal excretion. In the liver, it is metabolized by the polymorphic enzyme cytochrome P450 2D6 to the p-hydroxylation metabolite, p-hydroxymethamphetamine ( p-OHMA), and the N-demethylation product, amphetamine (Lin et al., 1997; Shima et al., 2008) . Both metabolites have been reported to circulate in plasma of methamphetamine abusers up to the micromolar range (Shima et al., 2008) . Amphetamine is also highly psychoactive and addictive with a mechanism of action similar to methamphetamine (Panenka et al., 2013) . p-OHMA is not psychoactive but acts as a cardiovascular agent with hypertensive and adrenergic effects (Römhild et al., 2003) .
Concurrent use of CYP2D6 substrates or inhibitors with methamphetamine and related designer
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6 drugs represents a risk of potential drug interactions leading to toxicity (Wu et al., 1997; Pritzker et al., 2002; Newton et al., 2005) .
Renal excretion is another major elimination pathway for methamphetamine and its metabolites. Approximately 37-54% of methamphetamine is recovered unchanged in the urine although more may be eliminated renally in CYP2D6 poor metabolizers (Kim et al., 2004) . The renal excretion rate of methamphetamine is highly dependent on urinary pH (Beckett and Rowland, 1965b; c, Cook et al., 1992 c, Cook et al., , 1993 . The fraction unbound of methamphetamine (fu) is about 0.8 (de la Torre et al., 2004) . The reported renal clearance of methamphetamine is highly variable (e.g. 67-371 mL/min) and much larger than glomerular filtration rate (GFR) in some individuals, suggesting that the drug is actively secreted by the kidney (Beckett and Rowland, 1965b; Kim et al., 2004) . PET imaging also revealed that methamphetamine is highly accumulated in the kidney (Volkow et al., 2010) . Both metabolites, p-OHMA and amphetamine, also undergo urinary excretion with a possible active secretion component (Shima et al., 2006) .
Little is currently known about the involvement of drug transporters in renal elimination and tissue distribution of methamphetamine and its metabolites. With a pKa of ~9.9, methamphetamine and its primary metabolites exist predominantly as protonated cations at physiological pH (de la Torre et al., 2004) . The reported or calculated LogD of methamphetamine, amphetamine and p-OHMA at 7.4 is -0.38, -0.62, and -1.11, respectively (Fowler et al., 2007) , suggesting a low passive membrane diffusion for the protonated species.
In rats, methamphetamine renal clearance was significantly reduced by cimetidine, a classic inhibitor of renal organic cation secretion system (Kitaichi et al., 2003) . In vitro studies have indicated that amphetamine is an inhibitor of human organic cation transporters (OCT) (Amphoux et al., 2006; Zhu et al., 2010) . However, the inhibition potency, substrate specificity, This article has not been copyedited and formatted. The final version may differ from this version. 
7 and transport kinetics of methamphetamine and metabolites towards renal organic cation uptake and efflux transporters have not been comprehensively characterized. This information is important for understanding the mechanisms involved in the disposition and potential drug-drug interaction of methamphetamine. The goals of this study were to characterize the interaction of methamphetamine and its major metabolites with human OCT1-3 and multidrug and toxin extrusion (MATE) transporter 1 and 2-K (hMATE1/2-K) and to identify the major transporters involved in renal secretion of methamphetamine, amphetamine and p-OHMA.
This article has not been copyedited and formatted. The final version may differ from this version. (Yin et al., 2015) . We focused our study on the dextro isoforms of methamphetamine and amphetamine because they are the psychoactive forms. In all our studies, methamphetamine and amphetamine refer to the dextro isoforms unless specified otherwise. Methamphetamine-D11 and amphetamine-D11 were purchased from Cerilliant Corporation (Round Rock, TX). Uptake and Inhibition Assays in HEK293 Cells. Flp-in HEK293 cells stably expressing hOCT1, hOCT2, hOCT3, hMATE1, hMATE2-K, hOAT1, and hOAT3 were previously generated in our laboratory (Duan and Wang, 2010; Duan et al., 2015; Yin et al., 2015) . The cells were cultured in high glucose DMEM media with 10% FBS, 1 mM L-glutamine, 100 U/mL penicillin, 100 g/mL streptomycin, and 150 g/mL hygromycin B supplementation at 37C
with 5% CO2 and high humidity. All cell culture plastic surfaces were coated with 0.01% poly-D-lysine to improve cell attachment. Uptake and inhibition assays were performed as previously described with modification for analysis of methamphetamine and its metabolites by LC-MS/MS (Duan and Wang, 2010; Duan et al., 2015; Yin et al., 2015) . Briefly, cells were seeded in Food and Drug Administration, 2012; Hillgren et al., 2013) . The concentration of metformin in inhibition experiments (11 M, 1 Ci/mL) was selected to be much lower than its Km values (780-1500 M) for the transporters tested (Koepsell et al., 2007; Tanihara et al., 2007) . Inhibition and kinetic experiments were performed during the initial rate period using a short incubation time as specified in figure legends. Transport experiments were performed in triplicate and repeated three times independently. Uptake was amphetamine, and p-OHMA levels were quantified using an LC-MS/MS system consisting of an AB-Sciex API 4500 triple quadrupole mass spectrometer (Foster City, CA) coupled with an LC-20AD ultra-fast liquid chromatography system (Shimadzu Co., Kyoto, Japan). The Turbo Ion
Spray interface was operated in positive ion mode. Ten microliters of cell lysate was injected onto an Agilent Eclipse Plus C18 column (1.8 m; 4.6x50 mm) running with an isocratic method consisting of 0.28 ml/min 0.2% formic acid in water and 0.12 ml/min acetonitrile. Mass transitions (m/z) were 150119, 13691, 166135, 16197, and 14798 for methamphetamine, amphetamine, p-OHMA, methamphetamine-d11, and amphetamine-d11, respectively. Data was analyzed using Analyst software version 1.6.2 (AB Sciex). Assay accuracy and precision were within 15% (20% for the lower limit of quantification).
Data Analysis.
Transport experiments were performed in triplicate and repeated three times independently. Data representation and replicates with specific n numbers are detailed in each figure legend. Transport kinetics were fitted using GraphPad Prism 6.0 (GraphPad Software, Inc., La Jolla, CA) for inhibitory interactions and uptake kinetics of hOCT1-3. WinNonLin Phoenix 6.4.0 (Certara, Princeton, NJ) was used for fitting hMATE apparent transport kinetics.
The IC50 values were calculated by fitting the Log inhibitor concentration versus the transporter specific uptake normalized to the vehicle control using the equation: (Brouwer et al., 2013) :
where V is the velocity of uptake, Vmax is the maximum velocity of uptake, S is the substrate concentration, Km is the Michaelis-Menten constant, and Pdif is the nonsaturable passive diffusion rate constant. Sigmoidal saturation kinetics of p-OHMA hOCT2 transport were obtained by fitting transporter mediated uptake to the Michaelis-Menten equation with a Hill slope for the substrate concentration and half maximal transport concentration (K1/2 in place of Km) after inspection of the Eadie-Hofstee plot (Copeland, 2000) :
Amphetamine hOCT2 specific uptake kinetics were fit to a biphasic Michaelis-Menten equation:
Results
Inhibitory Effect of Methamphetamine and its Metabolites on hOCT1-3 and hMATE1/2-K.
The transport activities of hOCT1, hOCT2, hOCT3, hMATE1, and hMATE2-K in the Flp-in HEK293 expression systems were first confirmed with metformin uptake in the presence or absence of the prototypical inhibitor cimetidine (Supplemental Fig. 1) . Methamphetamine, amphetamine, and p-OHMA inhibited metformin uptake by hOCT1-3 and hMATE1/2-K in a concentration-dependent manner ( Fig. 1 and Supplemental Fig. 2 ). The IC50 values were summarized in Table 1 . Methamphetamine and amphetamine were 4-20 fold more potent for hOCT1 and hOCT2 than for hOCT3, hMATE1, and hMATE2-K, with hOCT2 showing the greatest sensitivity to both psychostimulants (hOCT2 IC50 of 15.0  6.81 and 20.3  16.9 M, respectively). p-OHMA was a more potent inhibitor of hOCT1 than other transporters. Addition of the 4-hydroxyl group to the aromatic phenyl ring (p-OHMA) greatly increased binding to hOCT3 but decreased its potency toward hOCT2 as compared with methamphetamine.
Interestingly, the Hill slope of methamphetamine and amphetamine inhibition of hOCT1 and hOCT2 was approximately 0.5 (Table 1) . Conversely, the Hill slope of p-OHMA against hOCT2 was approximately 1.5. hMATE2-K also had steep Hill slopes ranging between 1.6 and 1.9 for methamphetamine and its metabolites. These Hill slopes suggest more complex interactions than simple competitive inhibition may be occurring with these transporters.
Inspection of methamphetamine and amphetamine dose-dependent inhibition of hOCT1 and hOCT2 revealed biphasic inhibition characteristics (Supplemental Fig. 3 Uptake of Methamphetamine and Metabolites by hOCT1-3, hMATE1, and hMATE2-K.
The substrate potential of methamphetamine, amphetamine, and p-OHMA was assessed by measuring the uptake of these compounds (1 M) in control cells and transporter expressing cells (Fig. 2) . After a 5-minute incubation, methamphetamine and amphetamine showed approximately 2-fold greater uptake in cells expressing hOCT2, hMATE1, and hMATE2-K.
p-OHMA accumulated extensively in hOCT1, hOCT2, hOCT3, and to a lesser degree hMATE1
but not at all in hMATE2-K transfected cells when compared to control cells (Fig. 2) . These data suggest that renal secretion of methamphetamine and its primary metabolites may involve the hOCT2/hMATEs pathway.
Interaction of Methamphetamine and Metabolites with Renal hOAT1 and hOAT3. While hOCT2 and hOAT1/3 respectively mediate renal secretion of organic cations and organic anions, some substrate and inhibitor overlap between hOCT and hOATs has been reported (Lai et al., 2010) . We then investigated if methamphetamine and metabolites interact with hOAT1 and hOAT3 ( Fig. 3 A and B) . hOAT1-and hOAT3-mediated PAH or ES uptake was completely suppressed by the reference inhibitor probenecid. In contrast, methamphetamine and amphetamine showed no inhibitory effect on hOAT1 or hOAT3 at 1 mM. Only p-OHMA showed a significant inhibition of hOAT1 and hOAT3 at 1 mM with 47  17 and 38  28% inhibition, respectively. Uptake studies showed that none of the compounds were substrates of hOAT1 or hOAT3 ( Fig. 3C-E) , suggesting a primary role of the hOCT2/hMATEs pathway in active renal secretion of these compounds. hMATE1/2-K transport studies were conducted after intracellular acidification to provide an outwardly directed proton gradient to drive substrate uptake because the MATE transporters (Fig. 5, Supplemental Fig. 5 , and Table 4 ).
Methamphetamine and Metabolites
This simultaneous fitting of both carrier-mediated and noncarrier-mediated uptake allowed for an estimate of the apparent Km values for hMATE1/2-K in the presence of a high passive permeability component (Table 3) .
Discussion
In spite of the major role of renal clearance in methamphetamine disposition the molecular mechanisms underlying the tubular secretion of methamphetamine and its major metabolites had not been fully elucidated (Caldwell et al., 1972; Kim et al., 2004; Carvalho et al., 2012) . Here we showed methamphetamine and its metabolites interact with hOCT1-3 and hMATE1/2-K at clinically relevant concentrations (Melega et al., 2007; Shima et al., 2009) . We further demonstrated that methamphetamine and amphetamine are substrates of hOCT2, hMATE1, and hMATE2-K, but not hOCT1or hOCT3. Interestingly, p-OHMA was a substrate of hOCT1-3 as well as hMATE1, but not hMATE2-K. Methamphetamine and its metabolites do not interact with renal organic anion transporters hOAT1 or hOAT3. Methamphetamine and its metabolites demonstrated complex inhibitory and substrate kinetics with hOCT2. Our data suggest that the hOCT2/hMATEs pathway is involved in renal secretion of methamphetamine and its metabolites, and that inhibition of hOCT2 and hMATEs by methamphetamine may lead to potential DDIs for drugs that are eliminated by the hOCT2/hMATE pathway.
The importance of renal elimination of methamphetamine has long been known; however, the exact molecular mechanisms of renal secretion had not been identified (Beckett and Rowland, 1965c; Caldwell et al., 1972) . Here we identified the hOCT2/hMATE pathway as being involved in the active renal secretion of methamphetamine and amphetamine.
Methamphetamine may be a potential victim of DDIs by inhibitors (e.g. cimetidine, zalcitabine, dolutegravir) of OCT2 and/or MATE transporters which could reduce its renal clearance and increase exposure (Jung et al., 2008; Reese et al., 2013) . Located at the apical membrane of renal proximal tubule cells, the MATE transporters function as proton/organic cation exchangers, which rely on the transmembrane proton gradient to drive organic cation secretion into the urine (Otsuka et al., 2005) . The pH dependence of methamphetamine and amphetamine renal excretion rates has long been known, where urine acidification increases renal excretion while urine alkalization has an opposite effect (Beckett and Rowland, 1965a; . The effect of urinary pH on methamphetamine or amphetamine renal excretion has been mostly attributed to the pH effect on ionization and membrane partitioning, which affects tubular reabsorption of these weak bases (Beckett and Rowland, 1965a; . Here, our data suggest that renal secretion of methamphetamine and amphetamine involves the pH-dependent MATE transporters.
Therefore, the increased excretion rates observed with acidic urine could be due to a combined effect of acidic pH in reducing partition-mediated reabsorption along with increasing MATEmediated tubular secretion.
The liver is the major site of methamphetamine metabolism. Intriguingly, methamphetamine and amphetamine were not substrates of hOCT1, the major OCT isoform responsible for hepatic uptake of organic cations. Therefore, hepatic uptake of methamphetamine and amphetamine may be facilitated by other transporters yet to be identified or be driven by passive diffusion. Interestingly, p-OHMA was transported by hOCT1, suggesting that the para hydroxyl group may be important for OCT1 transport selectivity of substituted amphetamines. hOCT1 may thus be involved in hepatic transport of p-OHMA.
In this study, we used metformin as the probe substrate because it is recommended as an in vitro and in vivo probe substrate for evaluating hOCT2, hMATE1, and hMATE2-K interaction studies by the International Transporter Consortium (ITC), Food and Drug Administration (FDA), and European Medicines Agency (EMA) (European Medicines Agency, 2012; Food and Drug Administration, 2012; Hillgren et al., 2013) . Substrate dependent inhibition has previously been demonstrated for OCTs with a number of substrates and inhibitors (Moaddel et al., 2005;  This article has not been copyedited and formatted. The final version may differ from this version. Gorbunov et al., 2008; Minuesa et al., 2009; Hacker et al., 2015; Yin et al., 2016) . For example, inhibition potencies of several clinical drugs towards hOCT2 were reported to be approximately 10-fold more potent when atenolol was used as the substrate as compared to metformin (Yin et al., 2016) . Due to the observed complex interactions, the apparent inhibition potencies of amphetamines may be highly dependent on the substrate. As an illicit drug, abusers may use methamphetamine while taking prescription medications. Testing the inhibition potencies with the specific hOCT substrate drugs used by methamphetamine abusers may be warranted to determine the likelihood of clinically relevant interactions.
Particularly high levels of methamphetamine abuse are reported in individuals receiving treatment for HIV and hepatitis who may be receiving multiple medications for treatment.
( Panenka et al., 2013; Volkow, 2013; Bracchi et al., 2015) . Importantly, numerous antiretrovirals (e.g. lamivudine, zalcitabine) interact with OCTs and rely on these transporters for cellular uptake into HIV-infected CD4 cells (Zhou et al., 2006; Jung et al., 2008) .
Methamphetamine and its metabolites inhibited the active transport of the probe substrate metformin by hOCT1-3 and hMATE1/2-K (Table 1) within the concentration range reported in abusers of methamphetamine (Melega et al., 2007; Shima et al., 2009) . The free plasma concentrations of methamphetamine in some abusers have been reported to be in the tens of micromolar range and even 130 M in one individual, indicating the potential to reach inhibitory concentrations of hOCT1-3 and hMATE1/2-K in vivo (de la Torre et al., 2004; Shima et al., 2008) . Inhibition of hOCT1 and hOCT2 may reduce intracellular levels of some antiretrovirals in HIV-infected CD4 cells, reducing their effective concentration and efficacy at the site of action (Minuesa et al., 2008 (Minuesa et al., , 2009 Wagner et al., 2016) . These potential distributional DDIs are (Table 3 , Fig. 5 ). Sigmoidal uptake kinetics may be characteristic of homotropic activation (Segel, 1976; Atkins, 2005) . Both a large binding pocket in the outward facing cleft allowing for spatially distinct binding as well as a distal allosteric binding site have been proposed for OCTs based on kinetics and biochemical analyses (Gorboulev et al., 1999; Harper and Wright, 2012; Koepsell, 2015) . The possible distal allosteric binding site has demonstrated very high affinity interactions with no transport observed in the concentrations range (e.g. 6-41 pM for MPP+) (Moaddel et al., 2005; Gorbunov et al., 2008; Minuesa et al., 2009; Koepsell, 2015) . Binding within the transportable region is generally a lower affinity interaction (e.g. 0.87-12.3 M for MPP+) with known substrates (Moaddel et al., 2005; Gorbunov et al., 2008; Minuesa et al., 2009; Koepsell, 2015) . Recent developments have also suggested the possibility of simultaneous binding of two substrates within the transport site (Harper and Wright, 2012; Koepsell, 2015) . In summary, our study determined the molecular mechanisms involved in transport and disposition of methamphetamine and its metabolites. Moreover, our studies showed that methamphetamine has the potential to inhibit hOCT and hMATE transporters at clinically relevant concentrations. Finally, we identified complex kinetic interactions between amphetamines and hOCT2. Our findings provide useful information that may be considered when prescribing medications to methamphetamine users to mitigate the risk of DDIs that may potentially compromise therapeutic efficacy and drug safety.
This article has not been copyedited and formatted. The final version may differ from this version. Methamphetamine, amphetamine and p-OHMA uptake in hMATE1-expresing cells was performed during initial linear uptake time at 5, 2, and 2 min respectively (A-C).
Methamphetamine and amphetamine hMATE2-expresing cells was performed during initial linear uptake time at 5 min (D and E). Incubations were performed at 37C and data were fitted with a Michaelis-Menten equation with a nonsaturable passive diffusion component (Eq. 3).
Each data point represents the mean ± S.D. from one representative experiment in triplicate.
Curves from two additional independent repeats are displayed in Supplemental Fig. 5 . The kinetic parameters in Table 3 are mean ± S.D. of the values from three independent experiments.
